Skip to main content

Table 2 Summary of acute and late toxicities

From: Phase I/IIa trial of androgen deprivation therapy, external beam radiotherapy, and stereotactic body radiotherapy boost for high-risk prostate cancer (ADEBAR)

 

18 Gy (n = 12)

21 Gy (n = 14)

Total (n = 26)

GU

Acute

Grade 1

6 (50%)

4 (29%)

10 (38%)

Grade 2

3 (25%)

3 (21%)

6 (23%)

Late

Grade 1

1 (8%)

1 (7%)

2 (8%)

Grade 2

0

1 (7%)

1 (4%)

GI

Acute

Grade 1

0

1 (7%)

1 (4%)

Late

Grade 1

1 (8%)

0

1 (4%)

Grade 2

1 (8%)

0

1 (4%)

  1. GI gastrointestinal, GU genitourinary